S 18986 is primarily investigated for its neuroprotective properties, particularly in the context of cognitive disorders and neurodegenerative diseases. It acts as a potent and selective agonist of the TrkB receptor, which is activated by brain-derived neurotrophic factor (BDNF). By mimicking BDNF activity, S 18986 enhances synaptic plasticity, supports neuronal survival, and promotes memory formation and learning processes.

This compound has shown promise in preclinical studies for improving cognitive function in models of Alzheimer’s disease, stroke, and age-related cognitive decline. It has also demonstrated potential in reducing neuronal damage following brain injury and in psychiatric conditions such as depression and anxiety, where neurotrophic support is compromised.

Due to its ability to cross the blood-brain barrier and its oral bioavailability, S 18986 is considered a favorable candidate for therapeutic development in central nervous system disorders. However, its use remains largely experimental, with ongoing research focused on optimizing dosing and evaluating long-term safety and efficacy.